ITALY – Aenova has announced a significant increase in cutting-edge aseptic production area at Latina, Italy, facility featuring a completely new high-speed flexible line for vials and prefilled syringes (PFS), as well as a completely new compounding area.
This area has the capacity to store more than 80 million vials and 180 million prefilled syringes for vaccines and biologics. Additional capacity expansions to a total of four high-speed filling lines are also planned.
Aenova has many years of experience as a global contract development and manufacturing organization (CDMO) in the production of sterile injectables.
Its unrivalled specialty ranges from pre-filled syringes and ampoules to liquid vials, lyophilized vials, and aseptic powder vials (powder filling in vials), as well as biological preparations and Bio Safety Level 1 and 2 (BSL) vaccines such as mRNA, DNA, viral vectors, protein subunits
This first high-speed flexible line can handle both vials and PFS products in the preferred sizes of 0.5 to 10 ml for prefilled syringes and 2 to 10 ml for ready-to-use vials.
The scope of supply is completed by quality control, packaging, and labeling, including serialization.
“With this expansion of our aseptic offering, Aenova becomes a premier solution partner for sterile technologies,” said Florent Bordet, senior vice president of Aenova’s sterile and liquid business unit.
With around 600 employees, the Aenova site in Latina is one of the Aenova Group’s largest production sites, producing and distributing pharmaceutical products worldwide.
The facility’s various buildings allow it to be in the market with a diverse site portfolio that includes injectable and oral solids for conventional medicines.
“We are very proud that with the new sterile filling line we will be able to make a major contribution to the global supply of vaccines and high-value biologics like recombinant proteins or monoclonal antibodies,” said Paolo Abbate, managing director of Haupt Pharma Latina.
Jan Kengelbach, CEO of Aenova Group, said, “Aenova is thus positioning itself as a provider of differentiated technologies with development and high-volume production capacities for small molecules as well as biologics. With an investment volume of around 16 million euros, the Latina plant is one of the larger investment projects that the Aenova Group is currently rolling out.”
Would you like to get regular updates of such news articles? Subscribe to our HealthCare Africa News, email newsletters, which provide the latest news insights from Africa and the World’s health, pharma and biotech industry. SUBSCRIBE HERE
Other articles you may like
-
National Institute for health and Care Excellence to issue guidelines for rare blood clot associated with COVID-19 vaccines
UK - The National Institute for Health and Care Excellence (NICE) is planning to develop a plan for the management and treatment of rare blood clots and hematological related conditions…
-
Statement for healthcare professionals: How COVID−19 vaccines are regulated for safety and effectiveness
GENEVA – WHO has issued a statement in collaboration with International Coalition of Medicines Regulatory Authorities (ICMRA) to healthcare professionals on how COVID-19 vaccines will be regulated for safety and…
-
WHO roots for efficient malaria vaccines distribution
SWITZERLAND – The WHO has approved the RTS,S vaccine, for widespread use among Sub-Saharan African children and other regions with moderate to high malaria transmission rates, but now, the international…